Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1980 Oct;77(10):6157–6161. doi: 10.1073/pnas.77.10.6157

ATP depletion as a consequence of adenosine deaminase inhibition in man.

M F Siaw, B S Mitchell, C A Koller, M S Coleman, J J Hutton
PMCID: PMC350233  PMID: 6969403

Abstract

Hereditary deficiency of the enzyme adenosie deaminase (adenosine aminohydrolase, EC 3.5.4.4) results in an immunodeficiency syndrome characterized by a marked reduction in circulating lymphocytes. We have administered 2'-deoxycoformycin, a potent inhibitor of adenosine deaminase, to a patient with a lymphoproliferative malignancy. The clinical consequences of pharmacologic inhibition of adenosine deaminase activity included an abrupt decrease in the lymphocyte count, abnormalities of renal and hepatic function, and hemolytic anemia. The plasma concentrations of adenosine and deoxyadenosine rose to peak values of 13 microM and 5 microM, respectively, and erythrocyte dATP levels increased to 110 pmol/10(6) cells over 9 days. There was a corresponding decrease in erythrocyte ATP levels from 128 to < 6 pmol/10(6) cells. A similar profound reductin in ATP occurred in the erythrocytes of a second patient. The rapid and unexpected depletion of ATP associated with dATP accumulation may account, at least in part, for the toxicity associated with 2'-deoxycoformycin administration. The inverse relationship of ATP and dATP raises major questions about the control of energy metabolism in erythrocytes.

Full text

PDF
6157

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carson D. A., Kaye J., Seegmiller J. E. Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J Immunol. 1978 Nov;121(5):1726–1731. [PubMed] [Google Scholar]
  2. Carson D. A., Kaye J., Seegmiller J. E. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977 Dec;74(12):5677–5681. doi: 10.1073/pnas.74.12.5677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang L. M., Bollum F. J. Doxynucleotide-polymerizing enzymes of calf thymus gland. IV. Inhibition of terminal deoxynucleotidyl transferase by metal ligands. Proc Natl Acad Sci U S A. 1970 Apr;65(4):1041–1048. doi: 10.1073/pnas.65.4.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen S. H., Ochs H. D., Scott C. R., Giblett E. R., Tingle A. J. Adenosine deaminase deficiency: disappearance of adenine deoxynucleotides from a patient's erythrocytes after successful marrow transplantation. J Clin Invest. 1978 Dec;62(6):1386–1389. doi: 10.1172/JCI109259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen A., Hirschhorn R., Horowitz S. D., Rubinstein A., Polmar S. H., Hong R., Martin D. W., Jr Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978 Jan;75(1):472–476. doi: 10.1073/pnas.75.1.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Coleman M. S., Donofrio J., Hutton J. J., Hahn L., Daoud A., Lampkin B., Dyminski J. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. J Biol Chem. 1978 Mar 10;253(5):1619–1626. [PubMed] [Google Scholar]
  7. Donofrio J., Coleman M. S., Hutton J. J., Daoud A., Lampkin B., Dyminski J. Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest. 1978 Oct;62(4):884–887. doi: 10.1172/JCI109201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fox I. H., Kelley W. N. The role of adenosine and 2'-deoxyadenosine in mammalian cells. Annu Rev Biochem. 1978;47:655–686. doi: 10.1146/annurev.bi.47.070178.003255. [DOI] [PubMed] [Google Scholar]
  9. Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972 Nov 18;2(7786):1067–1069. doi: 10.1016/s0140-6736(72)92345-8. [DOI] [PubMed] [Google Scholar]
  10. Henderson J. F., Brox L., Zombor G., Hunting D., Lomax C. A. Specificity of adenosine deaminase inhibitors. Biochem Pharmacol. 1977 Nov 1;26(21):1967–1972. doi: 10.1016/0006-2952(77)90003-x. [DOI] [PubMed] [Google Scholar]
  11. Hershfield M. S. Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine and adenine arabinoside. A basis for direct toxic effects of analogs of adenosine. J Biol Chem. 1979 Jan 10;254(1):22–25. [PubMed] [Google Scholar]
  12. Hershfield M. S., Kredich N. M., Ownby D. R., Ownby H., Buckley R. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest. 1979 Apr;63(4):807–811. doi: 10.1172/JCI109367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hirschhorn R., Roegner V., Rubinstein A., Papageorgiou P. Plasma deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in an adenosine deaminase-deficient child. J Clin Invest. 1980 Mar;65(3):768–771. doi: 10.1172/JCI109725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. KLENOW H., ANDERSEN B. Some enzyme reactions with adenine deoxyriboside polyphosphates. Biochim Biophys Acta. 1957 Jan;23(1):92–97. doi: 10.1016/0006-3002(57)90289-5. [DOI] [PubMed] [Google Scholar]
  15. KLENOW H. Further studies on the effect of deoxyadenosine on the accumulation of deoxyadenosine triphosphate and inhibition of deoxyribonucleic acid synthesis in Ehrlich ascites tumor cells in vitro. Biochim Biophys Acta. 1962 Dec 31;61:885–896. doi: 10.1016/0926-6550(62)90005-1. [DOI] [PubMed] [Google Scholar]
  16. Kredich N. M., Hershfield M. S. S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. Proc Natl Acad Sci U S A. 1979 May;76(5):2450–2454. doi: 10.1073/pnas.76.5.2450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lindberg U., Skoog L. A method for the determination of dATP and dTTP in picomole amounts. Anal Biochem. 1970 Mar;34:152–160. doi: 10.1016/0003-2697(70)90096-5. [DOI] [PubMed] [Google Scholar]
  18. Lowe J. K., Gowans B., Brox L. Deoxyadenosine metabolism and toxicity in cultured L5178Y cells. Cancer Res. 1977 Sep;37(9):3013–3017. [PubMed] [Google Scholar]
  19. Meuwissen H. J., Pollara B., Pickering R. J. Combined immunodeficiency disease associated with adenosine deaminase deficiency. Report on a workshop held in Albany, New York, October 1, 1973. J Pediatr. 1975 Feb;86(2):169–181. doi: 10.1016/s0022-3476(75)80463-x. [DOI] [PubMed] [Google Scholar]
  20. Mitchell B. S., Koller C. A., Heyn R. Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo. Blood. 1980 Sep;56(3):556–559. [PubMed] [Google Scholar]
  21. Mitchell B. S., Mejias E., Daddona P. E., Kelley W. N. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A. 1978 Oct;75(10):5011–5014. doi: 10.1073/pnas.75.10.5011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Palella T. D., Andres C. M., Fox I. H. Human placental adenosine kinase. Kinetic mechanism and inhibition. J Biol Chem. 1980 Jun 10;255(11):5264–5269. [PubMed] [Google Scholar]
  23. Parks R. E., Jr, Brown P. R. Incorporation of nucleosides into the nucleotide pools of human erythrocytes. Adenosine and its analogs. Biochemistry. 1973 Aug 14;12(17):3294–3302. doi: 10.1021/bi00741a022. [DOI] [PubMed] [Google Scholar]
  24. Parks R. E., Jr, Crabtree G. W., Kong C. M., Agarwal R. P., Agarwal K. C., Scholar E. M. Incorporation of analog purine nucleosides into the formed elements of human blood: erythrocytes, platelets, and lymphocytes. Ann N Y Acad Sci. 1975 Aug 8;255:412–434. doi: 10.1111/j.1749-6632.1975.tb29249.x. [DOI] [PubMed] [Google Scholar]
  25. Polmar S. H., Stern R. C., Schwartz A. L., Wetzler E. M., Chase P. A., Hirschhorn R. Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med. 1976 Dec 9;295(24):1337–1343. doi: 10.1056/NEJM197612092952402. [DOI] [PubMed] [Google Scholar]
  26. Polmar S. H., Stern R. C., Schwartz A. L., Wetzler E. M., Chase P. A., Hirschhorn R. Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med. 1976 Dec 9;295(24):1337–1343. doi: 10.1056/NEJM197612092952402. [DOI] [PubMed] [Google Scholar]
  27. Ullman B., Gudas L. J., Cohen A., Martin D. W., Jr Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease. Cell. 1978 Jun;14(2):365–375. doi: 10.1016/0092-8674(78)90122-8. [DOI] [PubMed] [Google Scholar]
  28. Valentine W. N., Paglia D. E., Tartaglia A. P., Gilsanz F. Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate. Science. 1977 Feb 25;195(4280):783–785. doi: 10.1126/science.836588. [DOI] [PubMed] [Google Scholar]
  29. Van der Weyden M. B., Buckley R. H., Kelley W. N. Molecular form of adenosine deaminase in severe combined immunodeficiency. Biochem Biophys Res Commun. 1974 Apr 8;57(3):590–595. doi: 10.1016/0006-291x(74)90587-7. [DOI] [PubMed] [Google Scholar]
  30. Wilson J. M., Mitchell B. S., Daddona P. E., Kelley W. N. Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts. J Clin Invest. 1979 Nov;64(5):1475–1484. doi: 10.1172/JCI109606. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES